Special Issue "Purinergic Signalling and Inflammation-Related Diseases"
Deadline for manuscript submissions: closed (15 November 2021) | Viewed by 24249
Interests: epilepsy; diagnosis; purinergic signaling; P2X7; microRNAs; Alzheimer’s disease
Interests: neuroscience; hypoxia; neonatal; neonatal encephalopathy; hypoxic-ischaemic encephalopathy; microRNA
Special Issues, Collections and Topics in MDPI journals
Interests: neurodegenerative diseases; Alzheimer disease; huntington disease; epilepsia; neurotransmission; purinergic signaling; TNAP; ATP; P2X and P2Y receptors
Inflammation is not only an important defence mechanism of cells against tissue injury, but inflammatory processes are also recognized to be one of the main contributors to numerous human diseases. Extracellular purinergic signalling is mediated by purine nucleotides and nucleosides such as adenosine and adenosine-triphosphate (ATP). Once released into the extracellular space, these molecules activate specific receptors: P1 receptors, which respond to the nucleoside adenosine, and P2 receptors, which respond to nucleotides such as ATP. Compelling evidence accumulated over the past number of decades has demonstrated purinergic signalling to mediate a broad range of cellular functions in health and disease. Among these, inflammation has attracted the most attention as one of the main pathways by which purinergic signalling contributes to diseases. Much progress has been made in dissecting purinergic signalling cascades, and, most importantly, the use of highly specific drugs targeting different components of the purinergic system has provided compelling evidence for a causal role of purinergic signalling in almost every human pathological condition ranging from cancer, to bone diseases, to diabetes, and to diseases of the brain. This present Special Issue will provide a broad overview of how purinergic signalling regulates inflammatory pathways and the contribution of purinergic signalling to acute and chronic diseases.
Dr. Tobias Engel
Dr. Eva María Jiménez-Mateos
Prof. Miguel Diaz-Hernandez
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- purinergic signaling
- release mechanisms
- extracellular nucleotides
- extracellular nucleotide degradation
- nucleoside and nucleotide receptors
- physiological processes and disease
- cellular stress